PT - JOURNAL ARTICLE AU - Eugene Sobngwi AU - Sylvain Zemsi AU - Magellan Guewo-Fokeng AU - Jean-Claude Katte AU - Charles Kounfack AU - Liliane Mfeukeu-Kuate AU - Armel Zemsi AU - Yves Wasnyo AU - Antoinette Assiga Ntsama AU - Arnaud Ndi-Manga AU - Joelle Sobngwi-Tambekou AU - William Ngatchou AU - Charlotte Moussi Omgba AU - Jean Claude Mbanya AU - Pierre Ongolo Zogo AU - Pierre Joseph Fouda TI - Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV) AID - 10.1101/2021.07.25.21260838 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.25.21260838 4099 - http://medrxiv.org/content/early/2021/07/29/2021.07.25.21260838.short 4100 - http://medrxiv.org/content/early/2021/07/29/2021.07.25.21260838.full AB - Objective We aimed to compare the safety and efficacy of a doxycycline-based regimen against the national standard guidelines (Hydroxychloroquine plus Azithromycin) for the treatment of mild symptomatic COVID-19.Methods We conducted an open-label, randomized, non-inferiority trial, in Cameroon comparing Doxycycline 100mg, twice daily for 7 days versus Hydroxychloroquine, 400 mg daily for 5 days and Azithromycin 500mg at day 1 and 250mg from day 2 through 5, in mild COVID-19 patients. Clinical improvement, biological parameters and adverse events were assessed. The primary outcome was the proportion of clinical cure at day 3, 10 and 30. Non-inferiority was determined by the clinical cure rate between protocols with a 20 percentage points margin.Results 194 participants underwent randomization and were treated with Doxycycline (n=97) or Hydroxychloroquine-Azithromycin (n=97). At day 3, 74/92 (80.4%) participants on Doxycycline versus 77/95 (81.1%) on Hydroxychloroquine-Azithromycin -based protocols were asymptomatic (p=0.91). At day 10, 88/92 (95.7%) participants on Doxycycline versus 93/95 (97.9%) on Hydroxychloroquine-Azithromycin were asymptomatic (p=0.44). At day 30 all participants were asymptomatic. SARS-CoV2 PCR was negative at Day 10 in 60/92 (65.2%) participants allocated to Doxycycline and 63/95 (66.3%) participants allocated to Hydroxychloroquine-Azithromycin. None of the participants were admitted for worsening of the disease after treatment initiation.Conclusion Doxycycline 100 mg twice daily for 7 days is as effective and safe as Hydroxychloroquine-Azithromycin, for preventing clinical worsening of mild symptomatic or asymptomatic COVID-19, and achieving virological suppression.Strengths and Limitations➢ This study is one of the first randomized trial, assessing the efficacy and tolerance of Doxycycline to treat COVID-19➢ It is one of the first to evaluate disease progression and need to hospitalization in mild or asymptomatic COVID-19➢ Patients will not receive identical treatments➢ Doxycycline has advantages in terms of availability, safety and cost compared to Hydroxychloroquine and Azytromycin➢ Though this study has encounter 7 lost to follow-up, this does not have a major influence on our results➢ These data will assist clinicians in their daily practice, and provide a new tool for the fight against COVID-19Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04715295Funding StatementThe study was partially sponsored by a special grant from the French Embassy in Cameroon. The study benefited of material support from the RSD institute Yaounde Cameroon and Yaounde Central Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical clearance from the Cameroon National Ethics Committee (2020/07/1585/L/CNERSH/SP).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability is subject to prior approval by the National Ethics Committee of Cameroon and the Minister of Public Health